Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 186, Issue 1, Pages 64-73Publisher
UNIV CHICAGO PRESS
DOI: 10.1086/341069
Keywords
-
Categories
Funding
- NHLBI NIH HHS [HL59239, HL067600] Funding Source: Medline
- NIAID NIH HHS [AI047544, AI44101] Funding Source: Medline
- NIGMS NIH HHS [GM08440] Funding Source: Medline
Ask authors/readers for more resources
Pseudomonas aeruginosa is a gram-negative pathogen causing life-threatening infections. Lung injury and the development of sepsis depend largely on the expression of type III secretion system (TTSS) virulence. TTSS functions as a molecular syringe to deliver toxins directly to the cytosol of cells, inhibit innate immune mechanisms, and prevent bacterial clearance. Polyclonal antibodies that bind to PcrV of P. aeruginosa inhibit the delivery of type III toxins and enhance the clearance of bacteria during acute lung infections. PcrV is a homologue of LcrV, a protective antigen in the Yersinia TTSS and an integral component of TTSS. In this study, a murine monoclonal antibody (MAb) to PcrV was generated: MAb 166, which is protective against P. aeruginosa when coinstilled with the bacterial inoculum or intraperitoneally transferred to mice. Fab fragments from MAb 166 prevent sepsis and death. The epitope bound by MAb 166 was mapped to the carboxyl-terminus of PcrV.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available